GlassScriptPhysician profile
Sindhu Avula
NPI 1811371974
$17,857.67
in general payments reported to CMS, 2019-2025
24 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $536 · 2020: $1,441 · 2021: $417 · 2022: $7,013 · 2023: $5,555 · 2024: $1,426 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $5,670 · Food and Beverage: $2,780.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $5,670.06 |
| Food and Beverage | $2,780.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $4,977.33 | 2020-2025 | General - Vascular Intervention, Varithena Administration Pack, Versacross Access Solution |
| Abbott Laboratories | $3,403.46 | 2019-2023 | Amplatzer Amulet, Xience Skypoint, Ultreon |
| Medtronic, INC. | $3,213.10 | 2022-2025 | Onyx Frontier, Abre, Micra |
| Bard Peripheral Vascular, INC. | $1,438.26 | 2022-2023 | Venclose Maven Catheter, Venovo |
| Becton, Dickinson and Company | $1,376.16 | 2023 | Venclose Maven Catheter |
| Biotronik INC. | $1,149.92 | 2022 | |
| Amgen INC. | $298.97 | 2019-2025 | Repatha, Repatha |
| Abiomed | $232.23 | 2023-2024 | Impella |
| Shockwave Medical, INC | $198.03 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astellas Pharma US INC | $198.00 | 2021 | |
| Medtronic Vascular, INC. | $196.31 | 2019 | |
| Penumbra, INC. | $179.58 | 2024-2025 | Ruby Coil, Indigo System |
| Esperion Therapeutics, INC. | $178.16 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $172.07 | 2020-2024 | Jardiance |
| Edwards Lifesciences Corporation | $126.37 | 2025 | Sapien 3 Ultra Resilia |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $94.32 | 2019-2021 | |
| Novo Nordisk INC | $93.46 | 2024-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $86.37 | 2024-2025 | |
| Pfizer INC. | $68.91 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $51.49 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $47.88 | 2023-2024 | Xarelto |
| Tactile Systems Technology INC | $37.40 | 2023-2024 | Entre Plus, Flexitouch Plus |
| Chiesi USA, INC. | $20.03 | 2022 | |
| Kiniksa Pharmaceuticals International, Plc | $19.86 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sindhu Avula listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.